Lotronex
(alosetron)Small molecule
0
Indications
3
Total Trials
0
Active Trials
0
Competitors
21
FDA Applications
NDA/BLA/ANDA regulatory filings
Clinical
Trials by Indication[1]
Irritable Bowel Syndrome2 trials
Regulatory
FDA Approval Timeline[3]
Mar 7, 2000
LOTRONEX
NDA NDA021107
Aug 11, 2000
LOTRONEX
NDA NDA021107
Jun 3, 2002
LOTRONEX
NDA NDA021107
Jun 7, 2002
LOTRONEX
NDA NDA021107
Mar 20, 2003
LOTRONEX
NDA NDA021107
Dec 23, 2003
LOTRONEX
NDA NDA021107
Dec 23, 2003
LOTRONEX
NDA NDA021107
Jan 31, 2005
LOTRONEX
NDA NDA021107
Feb 4, 2005
LOTRONEX
NDA NDA021107
Feb 18, 2005
LOTRONEX
NDA NDA021107
Mar 10, 2006
LOTRONEX
NDA NDA021107
Apr 1, 2008
LOTRONEX
NDA NDA021107
Sep 2, 2010
LOTRONEX
NDA NDA021107
Sep 2, 2010
LOTRONEX
NDA NDA021107
Apr 19, 2013
LOTRONEX
NDA NDA021107
May 8, 2014
LOTRONEX
NDA NDA021107
Jul 24, 2015
LOTRONEX
NDA NDA021107
Jan 7, 2016
LOTRONEX
NDA NDA021107
Jan 7, 2016
LOTRONEX
NDA NDA021107
Apr 3, 2019
LOTRONEX
NDA NDA021107
Sep 8, 2023
LOTRONEX
NDA NDA021107
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- LLegacy Health System